Patents by Inventor Arthur Pichler

Arthur Pichler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10842782
    Abstract: The present invention relates to a pharmaceutical composition containing a stable polymorph of rifaximin and a wicking agent as well as a method of preparing the same.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: November 24, 2020
    Assignee: Sandoz AG
    Inventors: Franz Xaver Schwarz, Arthur Pichler
  • Publication number: 20200262792
    Abstract: The present invention relates to a co-crystal of roxadustat with L-proline and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said roxadustat L-proline co-crystal, at least one pharmaceutically acceptable excipient and optionally at least one photostabilizing agent. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prevention of anemia in patients with end-stage renal disease (ESRD) and/or chronic kidney disease (CKD).
    Type: Application
    Filed: July 11, 2018
    Publication date: August 20, 2020
    Applicant: Sandoz AG
    Inventors: Hannes Lengauer, Arthur Pichler, Renate Margreiter, Thomas Gelbrich
  • Publication number: 20190008838
    Abstract: The present invention relates to a pharmaceutical composition containing a stable polymorph of rifaximin and a wicking agent as well as a method of preparing the same.
    Type: Application
    Filed: March 22, 2017
    Publication date: January 10, 2019
    Applicant: Sandoz AG
    Inventors: Franz Xaver Schwarz, Arthur Pichler
  • Patent number: 9732053
    Abstract: The present invention relates to 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate in crystalline form and to methods for the preparation thereof. In addition the present invention relates to solid pharmaceutical compositions for oral administration comprising an effective amount of the crystalline 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate. Moreover, the present invention relates to the use of crystalline 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate for the preparation of pharmaceutical compositions.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: August 15, 2017
    Assignee: LEK PHARMACEUTICALS D.D.
    Inventors: Andreas Hotter, Robert Ziegert-Knepper, Verena Adamer, Arthur Pichler
  • Patent number: 9534004
    Abstract: The present invention relates to novel crystalline forms of ceftaroline fosamil and to methods for their preparation. Furthermore the present invention relates to the use of the novel forms of ceftaroline fosamil for the preparation of an antibiotic medicament. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel forms of ceftaroline fosamil and to methods of preparing the same. Finally the present invention relates to pharmaceutical combinations comprising an effective amount of the novel forms of ceftaroline fosamil and ?-lactamase inhibitors.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: January 3, 2017
    Assignee: SANDOZ AG
    Inventors: Josef Wieser, Hubert Sturm, Arthur Pichler, Andreas Hotter, Nolwenn Martin, Christoph Langes, Ulrich Griesser
  • Publication number: 20160289202
    Abstract: The present invention relates to 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate in crystalline form and to methods for the preparation thereof. In addition the present invention relates to solid pharmaceutical compositions for oral administration comprising an effective amount of the crystalline 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate. Moreover, the present invention relates to the use of crystalline 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate for the preparation of pharmaceutical compositions.
    Type: Application
    Filed: June 30, 2014
    Publication date: October 6, 2016
    Applicant: LEK PHARMACEUTICALS D.D.
    Inventors: Andreas HOTTER, Robert ZIEGERT, Verena ADAMER, Arthur PICHLER
  • Publication number: 20160200750
    Abstract: The present invention relates to novel crystalline forms of ceftaroline fosamil and to methods for their preparation. Furthermore the present invention relates to the use of the novel forms of ceftaroline fosamil for the preparation of an antibiotic medicament. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel forms of ceftaroline fosamil and to methods of preparing the same. Finally the present invention relates to pharmaceutical combinations comprising an effective amount of the novel forms of ceftaroline fosamil and ?-lactamase inhibitors.
    Type: Application
    Filed: December 19, 2013
    Publication date: July 14, 2016
    Inventors: Josef Wieser, Hubert Sturm, Arthur Pichler, Andreas Hotter, Nolwenn Martin, Christoph Langes, Ulrich Griesser
  • Patent number: 9266868
    Abstract: Provided are a crystalline dihydrate of Rivaroxaban, processes for the preparation thereof, pharmaceutical compositions containing the crystalline dihydrate and processes for preparing and storing the pharmaceutical compositions. Also provided are a crystalline formic acid solvate of Rivaroxaban, processes for the preparation of crystalline Rivaroxaban formic acid solvate and the use of the Rivaroxaban formic acid solvate in the manufacture of the crystalline dihydrate of Rivaroxaban.
    Type: Grant
    Filed: July 5, 2011
    Date of Patent: February 23, 2016
    Assignee: SANDOZ AG
    Inventors: Johannes Ludescher, Hubert Sturm, Ulrich Griesser, Robert E. Ziegert-Knepper, Arthur Pichler, Mairi Haddow
  • Patent number: 9260389
    Abstract: The present invention relates to novel polymorphic forms of Saxagliptin Hydrochloride. The present invention also relates to methods of making polymorphic forms of Saxagliptin Hydrochloride.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: February 16, 2016
    Assignee: SANDOZ AG
    Inventors: Arthur Pichler, Josef Wieser, Christoph Langes, Milica Vukicevic
  • Patent number: 9062031
    Abstract: The present invention provides a reliable process for the preparation of polymorphic pure form A of Bazedoxifene x acetate. In addition, the present invention relates to a process of wet granulation of polymorphic pure form A of Bazedoxifene x acetate. The present invention also relates to pharmaceutical compositions comprising polymorphic pure form A of Bazedoxifene x acetate as well as to the use of cyclic ethers for the preparation of such pharmaceutical composition.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: June 23, 2015
    Assignee: SANDOZ AG
    Inventors: Arthur Pichler, Andreas Hotter, Christoph Langes
  • Publication number: 20140294962
    Abstract: The present invention provides a reliable process for the preparation of polymorphic pure form A of Bazedoxifene x acetate. In addition, the present invention relates to a process of wet granulation of polymorphic pure form A of Bazedoxifene x acetate. The present invention also relates to pharmaceutical compositions comprising polymorphic pure form A of Bazedoxifene x acetate as well as to the use of cyclic ethers for the preparation of such pharmaceutical composition.
    Type: Application
    Filed: December 21, 2011
    Publication date: October 2, 2014
    Applicant: SANDOZ AG
    Inventors: Arthur Pichler, Andreas Hotter, Christoph Langes
  • Patent number: 8785455
    Abstract: The present invention relates to a novel polymorph of Linagliptin benzoate and to methods for its preparation. Furthermore the present invention relates to the use of the novel polymorph for the preparation of a medicament. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel polymorph of Linagliptin benzoate.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: July 22, 2014
    Assignee: Sandoz AG
    Inventors: Andreas Hotter, Arthur Pichler
  • Publication number: 20140200252
    Abstract: The present invention relates to novel polymorphic forms of Saxagliptin Hydrochloride. The present invention also relates to methods of making polymorphic forms of Saxagliptin Hydrochloride.
    Type: Application
    Filed: October 2, 2013
    Publication date: July 17, 2014
    Applicant: SANDOZ AG
    Inventors: Arthur Pichler, Josef Wieser, Christoph Langes, Milica Vukicevic
  • Publication number: 20140121225
    Abstract: The present invention relates to a novel polymorph of Linagliptin benzoate and to methods for its preparation. Furthermore the present invention relates to the use of the novel polymorph for the preparation of a medicament. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel polymorph of Linagliptin benzoate.
    Type: Application
    Filed: May 9, 2012
    Publication date: May 1, 2014
    Applicant: SANDOZ AG
    Inventors: Andreas Hotter, Arthur Pichler
  • Patent number: 8563555
    Abstract: The present invention relates to a pharmaceutical composition comprising crystalline form Y of posaconazole. The pharmaceutical composition can be used to treat or prevent fungal infections.
    Type: Grant
    Filed: May 28, 2009
    Date of Patent: October 22, 2013
    Assignee: Sandoz AG
    Inventors: Josef Wieser, Arthur Pichler, Andreas Hotter, Ulrich Griesser, Christoph Langes, Christian Laschober
  • Publication number: 20130245017
    Abstract: The present invention relates to a novel crystalline dihydrate of Rivaroxaban, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline dehydrate and to processes for preparing and storing said pharmaceutical compositions. The invention also relates to a crystalline formic acid solvate of Rivaroxaban, processes for the preparation of crystalline Rivaroxaban formic acid solvate and to the use of said Rivaroxaban formic acid solvate in the manufacture of the crystalline dihydrate of Rivaroxaban.
    Type: Application
    Filed: July 5, 2011
    Publication date: September 19, 2013
    Applicant: SANDOZ AG
    Inventors: Johannes Ludescher, Hubert Sturm, Ulrich Griesser, Robert E. Ziegert-Knepper, Arthur Pichler, Mairl Haddow
  • Patent number: 8513224
    Abstract: The present invention relates to crystalline form C of Tigecycline dihydrochloride and to methods for the preparation of the same. Furthermore the present invention relates to the use of crystalline form C of Tigecycline dihydrochloride as an intermediate for the preparation of an anti-infective medicament. Moreover the present invention relates to pharmaceutical compositions comprising crystalline form C of Tigecycline dihydrochloride in an effective amount and to the use of crystalline form C of Tigecycline dihydrochloride as an anti-infective medicament.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: August 20, 2013
    Assignee: Sandoz AG
    Inventors: Andreas Hotter, Josef Wieser, Arthur Pichler, Martin Decristoforo
  • Patent number: 8435998
    Abstract: The present invention relates to crystalline form IV of posaconazole and pharmaceutical compositions comprising the same. The pharmaceutical composition can be used to treat or prevent fungal infections.
    Type: Grant
    Filed: June 25, 2009
    Date of Patent: May 7, 2013
    Assignee: Sandoz AG
    Inventors: Josef Wieser, Arthur Pichler, Andreas Hotter, Ulrich Griesser, Christoph Langes
  • Publication number: 20130012481
    Abstract: The present invention relates to crystalline forms A and B of Tigecycline hydrochloride and to methods for the preparation of the same. Furthermore the present invention relates to the use of crystalline forms A and B of Tigecycline hydrochloride as intermediates for the formulation of an anti-infective medicament. Moreover the present invention relates to pharmaceutical compositions comprising crystalline form A of Tigecycline hydrochloride in an effective amount and to the use of crystalline form A of Tigecycline hydrochloride as anti-infective medicament.
    Type: Application
    Filed: July 17, 2012
    Publication date: January 10, 2013
    Applicant: SANDOZ AG
    Inventors: Josef Wieser, Andreas Hotter, Arthur Pichler
  • Patent number: 8252946
    Abstract: The present invention relates to crystalline forms A and B of Tigecycline hydrochloride and to methods for the preparation of the same. Furthermore the present invention relates to the use of crystalline forms A and B of Tigecycline hydrochloride as intermediates for the formulation of an anti-infective medicament. Moreover the present invention relates to pharmaceutical compositions comprising crystalline form A of Tigecycline hydrochloride in an effective amount and to the use of crystalline form A of Tigecycline hydrochloride as anti-infective medicament.
    Type: Grant
    Filed: November 12, 2008
    Date of Patent: August 28, 2012
    Assignee: Sandoz AG
    Inventors: Josef Wieser, Andreas Hotter, Arthur Pichler